:’
The management of Autosomal Dominant Hypocalcemia Type 1 (ADH1), a rare genetic disorder characterized by hypoparathyroidism and associated calcium and magnesium imbalances, has been challenging. Recent developments in pharmacotherapy have offered new hope for affected patients. This article summarizes the positive results of the CALIBRATE Phase 3 clinical trial assessing the efficacy of encaleret, a novel calcilytic agent, in treating individuals with ADH1.
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by mutations in the calcium-sensing receptor (CaSR), leading to abnormal calcium homeostasis. Patients typically present with low serum calcium levels, elevated urine calcium excretion, and symptoms of hypocalcemia. Existing treatment options have often been suboptimal, emphasizing the need for new therapeutic approaches.
Study Overview:’
BridgeBio Pharma announced the results of the CALIBRATE study, a Phase 3 clinical trial evaluating the efficacy and safety of encaleret in adult patients diagnosed with ADH1. The primary aim was to assess whether encaleret could effectively increase serum calcium levels in this patient population.
Results:’
The CALIBRATE study met all pre-specified primary and key secondary efficacy endpoints. Notably, encaleret demonstrated a statistically significant increase in serum calcium levels among participants compared to placebo. Additionally, improvements in secondary outcomes related to quality of life and the frequency of hypocalcemic symptoms were observed. The safety profile of encaleret was consistent with expectations, with no new safety signals identified during the trial.
Discussion:’
The results of the CALIBRATE study suggest that encaleret may be a promising therapeutic option for patients suffering from ADH1, providing a targeted approach to managing the disorder’s hallmark features, including chronic hypocalcemia. The ability to meet primary and secondary endpoints highlights encaleret’s potential to change the clinical landscape for managing this condition.
Conclusion:’
The positive Phase 3 results of the CALIBRATE study position encaleret as a potentially effective treatment for ADH1. Further analysis of long-term outcomes and safety in diverse populations will be important for establishing encaleret as a standard treatment modality. Continued research and development in this area could greatly enhance care for patients afflicted with this rare disorder.
Keywords:’ Encateret, Autosomal Dominant Hypocalcemia Type 1, CALIBRATE study, Phase 3 clinical trial, calcium-sensing receptor, hypoparathyroidism.
Comments